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Background: Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition with a relapsing disease
course. Managing the relapsing nature of the disease causes daily stress for IBD patients; thus, IBD patients report
higher rates of depression and anxiety than the general population.
Mindfulness-based Cognitive Therapy (MBCT) is an evidence-based psychological program designed to help
manage depressive and stress symptoms. There has been no randomized controlled trial (RCT) testing the use of
MBCT in IBD patients.
The purpose of this pilot study is to test the trial methodology and assess the feasibility of conducting a large RCT
testing the effectiveness of MBCT in IBD.
Methods: The IBD patients, who were recruited from gastroenterology outpatient clinics at two Scottish NHS Boards,
were randomly allocated to an MBCT intervention group (n = 22) or a wait-list control group (n = 22). The MBCT
intervention consisted of 16 hours of structured group training over 8 consecutive weeks plus guided home practice
and follow-up sessions. The wait-list group received a leaflet entitled ‘Staying well with IBD’. All participants completed a
baseline, post-intervention and 6-month follow up assessment. The key objectives were to assess patient eligibility and
recruitment/dropout rate, to calculate initial estimates of parameters to the proposed outcome measures (depression,
anxiety, disease activity, dispositional mindfulness and quality of life) and to estimate sample size for a future large RCT.
Results: In total, 350 patients were assessed for eligibility. Of these, 44 eligible patients consented to participate. The
recruitment rate was 15 %, with main reasons for ineligibility indicated as follows: non-response to invitation, active
disease symptoms, planned surgery or incompatibility with group schedule. There was a higher than expected dropout
rate of 44 %. Initial estimates of parameters to the proposed outcomes at post-intervention and follow-up showed a
significant improvement of scores in the MBCT group when compared to the control for depression, trait anxiety and
dispositional mindfulness. The sample-size calculation was guided by estimates of clinically important effects in
depression scores.
Conclusions: This pilot study suggests that a multicentre randomized clinical trial testing the effectiveness of MBCT for
IBD patients is feasible with some changes to the protocol. Improvement in depression, trait anxiety and dispositional
mindfulness scores are promising when coupled with patients reporting a perceived improvement of their quality of life.
Trial registration: ISRCTN27934462. 2 August 2013.
Keywords: Mindfulness-based cognitive therapy, MBCT, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis,
Depression, Anxiety, Quality of life, Pilot randomised controlled trial* Correspondence: ms84@stir.ac.uk
1Centre for Health Science, School of Health Sciences, University of Stirling,
Inverness, Scotland, UK
Full list of author information is available at the end of the article
© 2015 Schoultz et al. Open Access This arti
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zecle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Schoultz et al. Trials  (2015) 16:379 Page 2 of 13Background
Impact of physical symptoms
Inflammatory bowel disease (IBD) is a group of idio-
pathic, chronic and disabling gastrointestinal conditions
with a relapsing disease course. The two main types are
Crohn’s disease (CD) and ulcerative colitis (UC), both
characterised by symptomatic periods (flare-ups) com-
bined with less-symptomatic periods (remission) [1].
IBD symptoms are caused by inflammation of the intes-
tinal mucosa (the lining of the gut), and the most com-
mon symptoms are bloody diarrhoea, vomiting, severe
pain and malnutrition [2, 3].
Managing and learning to cope with the relapsing na-
ture of the disease causes daily stress for IBD patients.
As a result, high rates of IBD patients report anxiety and
depression not only when in symptomatic periods, but
even in remission [4, 5]. The prolonged effects of pain,
anxiety and depression have damaging effects on psy-
chosocial functioning and quality of life (QoL) [6]. Poor
quality of life is further associated with symptom relapse
[7, 8]. Thus, anxiety, depression and relapse appear to be
concomitant in a self-perpetuating cycle with devastating
effects for IBD patients.
Current management and limitations
Medication is the first line of treatment for patients with
IBD. The therapeutic goal is to induce disease remission
and keep symptoms at bay for as long as possible [9]. In
addition, antidepressants are used for reducing distress,
anxiety and depression [10–12]. However, the medica-
tion approach on its own is not without limitations.
Firstly, it is reported that up to 40 % of IBD patients
regularly omit their prescribed medications with a third
of IBD patients still developing flare-ups even when
complying with prescribed medication [13, 14]. Further
to this, those using antidepressants often report unpleas-
ant side effects while others report that antidepressants
have no effect on their low mood or anxiety [15–17].
These limitations are a cause for concern and have
prompted researchers and clinicians to look at other
possible ways of symptom management and improving
psychosocial functioning.
Accordingly, an alternative evidence-based therapeutic
approaches focusing on stress management could have
the potential to manage disease flare-ups and ultimately
improve overall QoL [18–21].
Mindfulness-based cognitive therapy
Mindfulness-based cognitive therapy (MBCT) is an
evidence-based psychological group program designed
to help manage stress and depressive symptoms [22, 23].
The core skill taught in the program is mindfulness,
which is developing a non-judgemental awareness of
one’s own thoughts, emotions, body sensations and theirinteractions. The mindfulness skill is taught via a series
of meditation practices, cognitive behavioural exercises
and discussions [24]. The MBCT program curriculum is
structured and delivered over 8 weeks in a group setting.
Through practicing the curriculum exercises in the
group and at home, participants gradually develop better
awareness and understanding of their individual re-
sponses to stress (psychological or physical) and learn
new alternative ways to respond to stress. The evidence
suggests that at program completion, participants would
experience reduced negative effects from pain, distress,
anxiety and depressive symptoms [25].
The clinical effectiveness of mindfulness-based the-
rapies is evident in chronic pain conditions [26] and
chronic medical conditions [27] such as fibromyalgia,
cardiac and cancer patients, tinnitus and chronic fatigue
syndrome [28, 29]. Mindfulness-based intervention has
an anti-inflammatory effect on pro-inflammatory cyto-
kine profiles in patients with prostate and breast cancer
[30]. Systematic review and a meta-analysis of the effect-
iveness of mindfulness-based interventions on anxiety,
depression and psychological distress in patients with
chronic conditions have shown positive effects [31, 32].
Hence, the National Institute for Health and Care Excel-
lence guidelines recommends the MBCT program as a
preferred psychological therapy in the ‘clinical manage-
ment of persistent sub-threshold depressive symptoms or
mild, moderate or severe depression in adults (including
people with a chronic physical health problem)’ [33].
A recent RCT suggests that mindfulness-based therapy
has some benefit on IBD patients with IBS-like symp-
toms [34] and mindfulness-based therapy might be
useful for UC patients with high stress reactivity [35].
However, MBCT and its effect on depression, anxiety
and QoL have never been researched in a RCT with
both Crohn’s and ulcerative colitis patients.
Due to the literature gap, and in accordance with
the MRC guidance for development and evaluation of
complex interventions [36], the aim of this study was
to pilot the mindfulness-based cognitive therapy
(MBCT) program with inflammatory bowel disease
(IBD) patients and to evaluate the feasibility of con-
ducting a full-scale RCT that will test the effec-
tiveness of MBCT for IBD patients. The specific
objectives were as follows:
1. Objective one was to assess eligibility and
recruitment/dropout rate.
2. Objective two was to obtain initial estimates on
parameters of the proposed outcome measures
(depression, anxiety, quality of life, mindfulness and
disease activity).
3. Objective three was to estimate a sample size for a
large scale RCT.
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Design and ethics
This study was a two-centre, two-arm, exploratory pilot
RCT (MBCT treatment versus wait-list control group)
with three assessments (baseline, post-treatment and 6
months). The full protocol of the study reported in this
paper is the phase 1 of a two-phase pilot RCT described
elsewhere [37]. Phase 2 will be reported separately.
There were no deviations from the previously described
protocol. All pilot data were collected between April
2013 and March 2014. The study was approved by the
North Research Ethics Committee for North of Scotland
on 8 April 2013 (REC ref 13/NF/0018). NHS Highland
and NHS Grampian R&D Management Approval was
obtained on 9 April 2013 and 14 September 2013, re-
spectively. The trial was registered on the ISRCTN regis-
ter (ISRCTN27934462) on 02 August 2013.
Setting and recruitment
The study took place across two national health boards
in the north of Scotland, a broad geographical area com-
prising urban and remote rural locations with approxi-
mate population of 800,000 people. Recruitment focused
on outpatient gastroenterology clinics in the two areas.
Between May and October 2013, clinical staff at par-
ticipating gastroenterology outpatient clinics scanned
and identified potential participants that met the study
inclusion criteria. Then, either study invitation packs
were sent to patients with researchers contact details or
patients seen consecutively in clinics were approached
with the study information. All study information was
co-designed with patients from the patient-involvement
group [38]. Interested participants then registered their
interest with the researcher by telephone or email. This
was followed up with a screening visit with the re-
searcher and then informed written consent was ob-
tained. The inclusion criteria were broad enough to
allow the sample to be representative of those diagnosed
with IBD. Patients were excluded if they had a major
psychiatric illness or alcohol dependency, were sched-
uled for surgery during the study period; if they were
participating in other pharmacological or psychological
intervention study or had a recent change of antidepres-
sants or exacerbated symptoms. A full list of inclusion
and exclusion criteria is in Additional file 1.
Randomisation
Randomisation was performed after all participants had
given written consent and baseline data had been col-
lected. Participants were randomly allocated to the inter-
vention ‘MBCT group’ or ‘wait-list control group’ in a 1:1
ratio. To ensure similarity between the groups, ran-
domization was stratified on two variables - disease type
and sex. Random allocation was computer generated. Apermuted block randomization procedure with randomly
varied block sizes was used. Blinding of researchers and
patients was not possible because the intervention in-
volved attending a course. Participants were informed of
the results of randomization by email or letter (depending
on their preference).Minimising bias
Bias can occur at any stage of planning, data collection,
analysis or publication [39]. The following steps were
taken to minimise systematic errors or bias and improve
rigour: all participants self-completed all of the question-
naires, data entry was done by the lead researcher and
was independently checked by a second person, and data
analysis was done by two researchers independently.MBCT intervention
The MBCT program used in this study closely followed
the 8-week MBCT manual developed by Segal et al. [23].
It comprised 8 weekly face-to-face group sessions, each
lasting approximately 2 hours. The sessions included fa-
cilitator instruction, group practice and instructions for
home practice. In brief, the manual followed a similar
layout for each session and opened with introduction to
a new theme (see Additional file 2 for themes), followed
by short opening meditation and discussion. The group
was then introduced to a new practice/exercise, which
was followed by reflection, then review and instruction
for at-home practice and followed by sitting meditation.
A sample list of activities for session 1 is presented in
Additional file 3.
The type of practices used in the MBCT curriculum
are a combination of formal exercises/meditations such
as body scan, sitting and walking meditation and mind-
ful stretching; cognitive behavioural exercises and infor-
mal practices and discussions with personal reflections
of everyday life events. A sample audio file of one of the
meditations is available in Additional file 4.
Part of the intervention involved home practice assign-
ments aimed at reinforcing the in-group learned tech-
niques and strategies. The recommended home practice
was up to 45 minutes a day for 6 days a week, with
guided audio CD and outlined instructions for the home
practice. The hand-outs and audio CD’s used for home
practice are ready available from the published books re-
spectively [23, 40].
To further reinforce the learned practices, the manual
suggests that an additional full day of mindful practice
take place between weeks 6 and 7 (usually on a weekend).
In the full day of practice participants go through all the
learned meditations one after another in silence, with the
group reflection and discussion taking place at the end of
the practice day. Due to resource constraint, in this study,
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they have completed the 8-week course.
The program was delivered by two experienced MBCT
practitioners who have been briefed on the key concerns
and difficulties that IBD patients experience, as well as
on the nature of the disease. Both practitioners had com-
pleted an 8-week MBCT course, maintained a personal
practice and had facilitated a number of 8-week MBCT
programs each over the previous five years, fulfilling the
good practice guidance for teaching mindfulness-based
courses [41].
Each weekly session was audio recorded except the
last one due to failure of the recording device.
Wait-list control
The control group continued to receive their standard
care and in addition they received a leaflet entitled ‘Staying
well with IBD’. The leaflet is readily available to download
from the Crohn’s and Colitis UK website, but participants
in the study received a printed copy [42]. After the
6-month follow-up data were collected, the wait-list
group had the opportunity to attend a MBCT program.
Data collection, assessments and outcomes measures
As this was an efficacy trial with the primary objective
being to pilot the MBCT program with IBD patients and
to assess the feasibility of the program and methodology
in a definitive RCT, data were collected to assess trial
feasibility [43]. Data were also collected on the proposed
outcome measures to be tested in a definitive RCT.
Feasibility criteria and measures
The guidance for a good pilot study suggests setting a pre-
determined criterion for measuring the success of feasibil-
ity [44]. While literature suggests various figures [45, 46],
the feasibility criterion for assessing success of feasibility
in this study was set to at least 10% recruitment rate.
Screening and recruitment data were collected by the
lead researcher on all patients considered for the study.
Information was also collected on patients excluded with
reasons for exclusion at each stage, date of recruitment
and randomisation. A full CONSORT diagram [47] of
subject flow is presented in Fig. 1 and a CONSORT
checklist is available in Additional file 5.
To assess treatment compliance and to inform the es-
timated attrition rates for a full trial, facilitators recorded
a weekly attendance log for each participant.
Baseline characteristics
Demographic data (age, sex, marital status, education
and income) was obtained to assess the success of ran-
domisation [48]. Data were also collected on participants
locality (rural or urban), to assess if there is any relation-
ship between rurality and drop-out rates.Proposed outcomes measures
The following proposed outcomes were assessed at base-
line, post intervention and at 6 months: depression,
anxiety, dispositional mindfulness, disease activity and
quality of life.Depression
Low mood and depression symptoms was measured
with the Beck’s depression inventory (BDI-II) [49]. The
BDI-II is an established self-reporting tool for screening
depression, and it consists of 21 group of statements,
where the participant rates each statement on a four-
point scale of severity. The statements refer to the last 2
weeks. The interpretation is based on a 0 to 63 total score,
with higher total scores indicating more severe depressive
symptoms. Previous studies indicate high test-retest reli-
ability as well as high internal consistency [50, 51].Anxiety
Anxiety was measured by the State and Trait Anxiety
Inventory (STAI). STAI is a widely used self-reporting
tool consisting of two parts: STAI- Y1 and STAI-Y2.
Both parts consist of a 20-item scale, with STAI- Y1
measuring the state or current anxiety (anxiety related
to an event) and STAI-Y2 measuring the trait or chronic
anxiety (anxiety level as a personal characteristic). Partic-
ipants are asked to rate each individual statement on a
four-point scale, depending on how well each statement
is describing the participants mood. The rating options
are ranging from “not at all” to “very much so”. Each of
the two parts of the STAI scores range between 20 and
80, with higher scores being positively correlated with
higher levels of anxiety [52]. This tool is widely used to
measure anxiety and regarded as highly reliable [8], but
is particularly useful for IBD patients as each of the
statements is focused on the cognitive symptoms of
anxiety rather than mixing it with the somatic symptoms
related to the disease.Dispositional mindfulness
Dispositional mindfulness or mindful attention was mea-
sured using the Mindful Attention Awareness Scale
(MAAS). This scale consists of 15 items that measure
the frequency of which participants experience mindful
awareness and mindful attention on a six-point Likert
scale. The scale items refer to statements about everyday
experiences graded by participants, using a scale of 1 to
6, which indicates how often each experience occurs.
Higher scores reflect higher levels of dispositional mind-
fulness. The validation of this tool has been examined in
a series of studies indicating strong psychometric prop-
erties and validity [53, 54].
Fig. 1 Consort diagram describing flow of patients through study
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Disease activity was assessed with an eight-item question-
naire Crohn’s Disease Activity Index (CDAI) for Crohn’s
patients [55, 56] and six-item questionnaire Simple
Clinical Colitis Activity Index (SCCAI) for ulcerative col-
itis patients. The CDAI has been validated prospectively
and is the gold standard for the evaluation of CD disease
activity [57, 58]. A decrease in the CDAI of 70 or 100
points has been defined as a CDAI-70 and CDAI-100 clin-
ical response, respectively [59]. The SCCAI, as well as the
CDAI, is a subjective disease activity index and rates over-
all well-being, daytime and night-time bowel movements,
bowel movement urgency and rectal bleeding. SCCAI dis-
ease activity scores ≥3 correlate with active disease [60].
Quality of life
All participants were required to complete a disease-
specific IBD quality of life (IBDQ) questionnaire. Althoughthe questionnaire used in this study closely followed the
validated IBDQ 32-item questionnaire that measures
health-related QoL in IBD patients, the questionnaire was
modified from the original version of the IBDQ. What
remained were the same the four domains, including bowel
symptoms, systemic symptoms, emotional factors and so-
cial factors. The only difference was that participants rated
their symptom experience over the previous 2 weeks on a
four-point Likert scale ranging from 0 (worse health) to 3
(best health) rather than 7-point. This was to reduce the
burden of patients. Thus, scores ranged from 0 to 96 rather
than 32 to 224 in the original IBDQ, and similarly, low
scores indicated more severe disease activity and/or higher
emotional and social dysfunction. IBDQ directly assesses
the participant’s view on her/his disease and a relatively
good correlation between the IBDQ and a widely used
measure of disease activity, the Crohn’s Disease Activity
Index is reported [61, 62].
Table 1 Reasons for discontinuing mindfulness-based cognitive
therapy (MBCT)
Reason Number of
participants (%)
Number of sessions
attended
From rural
area (%)
Not for them 2 (9) 1 1 (4.5)
Travel time 2 (9) 1 2 (9)
Family illness/carer 1 (4.5) 1 1 (4.5)
Work schedule
interference
2 (9) 1 0 (0)
Family illness/carer 1 (4.5) 3 0
Acquired unrelated
sickness
1 (4.5) 3 1 (4.5)
Seized eligibility
before start of
intervention
1 (4.5) 0 0 (0)
Total 10 (45) 10 5 (22.7)
Table 2 Data completion for research outcomes
Control MBCT Total Missing/Invalid
Total consented and
randomised
22 22 44 n/a
Dropped out
Prior start of MBCT 0 1 1 n/a
Prior to MBCT completion 10 9 19 n/a
Prior to 6 month follow up 0 0 0 n/a
Baseline BDI-II 22 21 43 1
Post-MBCT completion BDI-II 12 12 24 20
6-month follow-up BDI-II 12 12 24 20
Baseline STAI-Y1 21 20 41 3
Post-MBCT completion STAI-Y1 12 12 24 20
6-month follow-up STAI-Y1 12 12 24 20
Baseline STAI-Y2 22 20 42 2
Post-MBCT completion STAI-Y2 12 12 24 20
6 month follow up STAI-Y2 12 12 24 20
Baseline MAAS 22 22 44 0
Post MBCT completion MAAS 12 12 24 20
6-month follow-up MAAS 12 12 24 20
Baseline IBDQ 21 21 42 2
Post-MBCT completion IBDQ 12 12 24 20
6-month follow-up IBDQ 12 12 24 20
Baseline DA 21 22 23 1
Post-MBCT completion DA 12 12 24 20
6-month follow-up DA 12 12 24 20
Abbreviations: BDI-II Beck Depression Inventory II, DA Disease Activity, IBDQ
Inflammatory Bowel Disease Questionnaire, MAAS Mindfulness Attention
Awareness Scale, MBCT Mindfulness Based Cognitive Therapy, STAI-Y1 and
Y2-State Trait Anxiety Inventory
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Due to the nature of this pilot study, a formal sample
size calculation was not performed. The determined
sample size of n = 40 was calculated based on the esti-
mated number of participants expected to complete the
8-week program. Full information on how n = 40 was
achieved is reported elsewhere [37].
Analysis
In line with the good practice guidance for analysis of
any pilot study, the primary analysis of the study was de-
scriptive [63, 64]. Descriptive data were calculated repre-
senting frequencies, means and standard deviations for
all continuous data and n (%) for categorical data.
Further analysis was done to determine initial estimates
of the parameters for the proposed outcome measures, for
example, the mean and standard deviation required for
sample size calculation for a future large RCT [65]. As this
was an efficacy trial, the type of analysis was as per proto-
col [43]. For this, analysis of mixed covariance (ANOVA)
statistical method was used. This method looked at the
changes in outcome scores over time in the two different
groups. A significance level of 5 % was chosen for pro-
posed hypothesis testing. Data analysis was conducted
using IBM SPSS version 19 software.
Results
Objective one: trial methodology
Eligibility, recruitment and dropout rates
Recruitment, intervention delivery and follow-up took
place between May 2013 and March 2014. A total of 350
consecutive patients were assessed for eligibility. Study
invitations were sent to 297 eligible patients and 44 con-
sented to participate, giving a recruitment rate of 15 %.
A consort diagram of patient flow is presented in Fig. 1.
Although a total of 243 patients did not respond to
study invitation, a recruitment target of 40 was achieved.
In total, 44 participants were randomised, with 22 in
each arm. Table 1 summarises reasons for discontinuing
MBCT, how many sessions each of the participants who
dropped-out attended and if they were from a rural or
urban area. One participant randomised to the inter-
vention arm ceased eligibility (had a flare-up) before the
commencement of intervention, and one participant ran-
domised to the wait-list control arm ceased eligibility
(attended mindfulness course elsewhere while in the con-
trol) after randomisation. Data for another 18 participants
were lost to follow-up (9 in each arm). In addition, 95.5 %
of participants were recruited from one board only.
Protocol adherence and success of data collection strategy
Completion of data collection at each time point is sum-
marised in Table 2. This also indicates the degree of ad-
herence to the research protocol. A log of attendance
Table 3 Mindfulness-based cognitive therapy (MBCT) attendance log
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Sessions Missed Sessions attended
1. x 1 7
2. x x x 3 5
3. x x x x 4 4
4. x x x x x x x 7 1
5. x 1 7
6. 0 8
7. x x x x x x x 7 1
8. x x x x x 5 3
9. 0 8
10. 0 8
11. x x x x x 5 3
12. x x x x x x x 7 1
13. x 1 7
14. 0 8
15. 0 8
16. x x x x x x x x 8 0
17. x x x x x x x 7 1
18. 0 8
19. x x x x x x x 7 1
20. x x x x x x x 7 1
21. x x x x x x x 7 1
22. 0 8
X-missed a session
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at least four sessions from the intervention over the 8
weeks (Table 3). An overall of 24 participants (56 %)
completed all assessments at post-intervention and
6-month follow-up.Baseline characteristics
Table 4 shows the age, sex, income, disease type, marital
status and education distribution for the 44 consented
participants. An independent T-test between groups at
baseline showed no significant differences between the
two arms for baseline characteristics.Objective two: initial estimates on parameters of the
proposed outcome measures (depression, anxiety,
dispositional mindfulness, disease activity and quality
of life)
A mixed ANOVA was conducted on all dependent vari-
ables: depression, anxiety, dispositional mindfulness, dis-
ease activity and quality of life. All assumptions with
regard to outliers, normal distribution, homogeneity of
variances and co-variances and sphericity were tested
and met. The means and standard deviation (S.D.) of allproposed outcomes for MBCT and the wait-list group
over the three time points are presented in Table 5.
(BDI-II) depression
Per-protocol analysis revealed an improvement in de-
pression scores in the MBCT group at post-intervention
and follow-up. There was a statistically significant inter-
action between the MBCT group and time on depression
scores (F(4,84) = 3,975, P = .027, partial η2 = .173).
(STAIY1) state anxiety
There was an improvement in state anxiety score in the
intervention arm over the post-intervention and follow up
period; however, the difference between the arms over
time was not statistically significant (F(4,84) = 2,809,
P = .083, partial η2 = .135).
(STAIY2) trait anxiety
When the per-protocol population was analysed, the trait
anxiety scores between the two arms showed a statistically
significant interaction between the MBCT group and the
time on trait anxiety scores (F(4,84) = 3,286, P = .048, par-
tial η2 = .147).
Table 5 Means and standard deviation of proposed outcomes at ba
Measured outcome Condition Baseline
Mean S.D. N
BDI-II MBCT 14.36 9.520 22
Wait-list 15.57 7.291 21
STAIY1 MBCT 38.76 11.397 21
Wait-list 37.26 10.429 20
STAIY2 MBCT 45.50 10.318 22
Wait-list 47.45 8.666 20
MAAS MBCT 3.6586 .7935 22
Wait-list 3.4005 .6655 22
CDAI MBCT 101.56 60.28052 3
Wait-list 145.866 84.76086 8
SCAI MBCT 4.3750 2.77424 8
Wait-list 2.2500 2.62996 4
IBDQ MBCT 34.3333 12.17922 21
Wait-list 36.5714 14.40684 21
Depression (BDI-II); State anxiety (STAIY1); Trait anxiety (STAIY2); Dispositional mind
Ulcerative colitis activity index (SCAI); Disease specific QoL (IBDQ)
Table 4 Baseline characteristics
Intervention Control
Age (years) (n, mean (sd)) 22, 48.59 (12.046) 22, 49.68 (15.370)
Sex (F (n,%), M(n,%)) 16,(72.7) 6,(27.3) 18,(81.8) 4,(18.2)
Income (n, %)
less 10K 1 (4.5) 6 (27.3)
10K-19K 7 (31.8) 6 (27.3)
20K-29K 4 (18.2) 2 (9.1)
30K-39K 4 (18.2) 4 (18.2)
40K-50K 2 (9.1) 3 (13.6)
50K+ 4 (18.2) 1 (4.5)
Disease type
CD (n, %) 9 (40.9) 12(54.5)
UC (n, %) 13(59.1) 10(45.5)
Marital status
Single (n, %) 5 (18.2) 9 (40.9)
Married/cohabiting (n, %) 15 (68.2) 8 (36.4)
Widowed (n, %) 0 (0) 3 (13.6)
Separated/divorced (n, %) 3 (13.6) 1 (4.5)
Education (High school n, %) 9 (40.9) 9 (40.9)
(Diploma n, %) 9 (40.9) 7 (31.8)
(Degree or above n, %) 4 (18.2) 5 (27.2)
CD Crohn's Disease, F female, M male, N number, SD standard deviation,
UC Ulcerative colitis
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Dispositional mindfulness scores showed an improve-
ment in the MBCT arm in comparison to the wait-list,
with a statistically significant interaction between the
MBCT group and time on dispositional mindfulness
(F(4,84) = 3,998, P < =.034, partial η2 = .174).
DA (disease activity)
Although disease activity showed improvement in the
MBCT arm, there was no statistically significant inter-
action between the MBCT and time on Crohn’s disease
activity scores (F(4,84) = 1,410, P = .277, partial η2 = .168)
or between the MBCT group and time on ulcerative colitis
activity scores (F(4,84) = 2,927, P = .083, partial η2 = .268).
IBDQ (IBD quality of life)
While there was a small improvement in the IBDQ score
at the 6-month follow-up, there was no statistically sig-
nificant interaction between the MBCT group and time
on quality of life scores (F(4,84) = .845, p = .437, partial
η2 = .043).
Objective three: sample size calculation
The sample size for a full RCT is calculated on the basis
of the proposed primary hypothesis and clinically mean-
ingful effect sizes of changes in depression scores BDI. A
change of five scores in BDI is deemed to be clinically
meaningful [66]. We have based our sample size estimate
on the most conservative standard deviation of 11.89. To
detect a mean difference in BDI score of five points at
week 8 with a two-sided significance level of 5 % and
power of 80 % with equal allocation to two arms wouldseline, post-MBCT and follow-up
Post-MBCT 6 month Follow up
Mean S.D. N Mean S.D. N
10.67 13.996 12 13.75 16.355 12
14.23 10.158 12 14.17 9.173 12
37.74 15.635 12 39.67 16.183 12
43.67 5.806 12 45.16 9.347 12
41.67 16.396 12 42.58 16.368 12
47.08 6.431 12 45.92 7.354 12
4.2758 1.0342 12 4.1450 1.1675 12
3.5769 .5802 12 3.5433 .7867 12
69.0000 86.15683 3 18.6833 15.01002 3
101.8750 66.69212 8 139.7150 83.44660 8
3.8750 3.39905 8 5.5000 4.17475 8
4.5000 3.0000 4 5.0000 4.39697 4
31.0833 18.0225 12 34.8333 23.7863 12
33.9167 15.1864 12 36.8333 12.0667 12
fulness (MAAS); Crohn’s disease activity index (CDAI)
Schoultz et al. Trials  (2015) 16:379 Page 9 of 13require 90 patients in each arm of the trial. To consider
and allow a 44 % drop-out (finding from this study), then
129 IBD patients should be recruited per arm (258 in
total).
Discussion
This paper describes a pilot randomised control trial of
Mindfulness-based Cognitive Therapy for IBD. The re-
sults showed that it would be feasible to conduct a full
RCT. In conducting this investigation, we have identified
areas of critical importance if a subsequent study of
MBCT for IBD is to going to be conducted. These areas
are related to recruitment and retention, data collection
and trial design as well as to the intervention.
Objective one: trial methodology
Consent, recruitment and retention
Consent and baseline Recruitment for this trial was dif-
ficult, even though the recruitment target was reached.
It was estimated that each individual appointment for
discussing consent and making baseline assessments
would last approximately 45 minutes, but in reality
lasted approximately 1.5 hours. This was not due to the
assessments taking longer, but due to fact that for most
of the participants this was an opportunity for them to
voice their difficulties, particularly the stress and anxiety
related with the condition. Because much of the infor-
mation was shared before actually signing the consent
form, this information was not captured for analysis. In
addition, tester sessions were offered to prospective par-
ticipants before they made a decision to participate. This
idea came from some of the prospective participants
wanting to ‘test drive’ the intervention. Although only
three signed up for the tester session, all three partici-
pants that came for a tester session decided to partici-
pate and completed all the trial assessments.
Recruitment Although the recruitment was conducted
in two NHS Boards (approximately 2,341 IBD patients),
95.5 % of participants were recruited from one of the
boards. A number of strategies were devised to maxi-
mise the number of patients screened for eligibility into
the study. The most effective strategy of recruitment
(93.2 %) was through a letter of invitation send by an
IBD specialist nurse. We believe there are at least two
possible explanations regarding this. Firstly, it is possible
that this strategy was most effective due to the fact that
there was already an established trusted relationship be-
tween the patient and the IBD nurse, and the response
to the invitation to participate reflected that trust. And
secondly, it could be the actual high number of letters
that were sent to patients could be the reason for the
good response rate. Nonetheless, this strategy was a
lengthy process of going through IBD patient recordsand sending invitation and information packs every week
for few months. To improve future recruitment, litera-
ture suggests three key areas of relevance: infrastructure,
professional and public engagement with research, and
methodological innovation [67]. A dedicated recruitment
person working closely with the IBD nurse, using
current networks such as Crohn’s and Colitis UK to aid
recruitment or offering incentives for prospective par-
ticipants could make this process more effective. These
suggestions should be considered if a full RCT is to be
conducted.
Retention Both arms experienced an equally high drop-
out rate of 44 %, with 33 % attending only one session in
the intervention arm. If we only look at the intervention
arm, the high drop-out rate suggests that the inter-
vention may not be suitable or acceptable to all IBD
patients. However, whereas seven participants (33 %)
attended only one session, only two of them said the inter-
vention was not for them. The reasons that the other five
participants gave were that they realised the travel time
commitment was too much (2), there was work schedule
interference (2) and there was a family illness (1). Al-
though at recruitment, the commitment required for the
course was particularly highlighted, it appears that the
participants either overestimated their other commit-
ments and travel time or were overenthusiastic to start
with and had a decline in motivation or had a change of
circumstances by the time the intervention started. The
last one is a possibility if taken into consideration that the
time between recruitment and start of intervention was
around 5 months for some participants [68] and should
be addressed in any future trial.
If we look at the wait-list arm, the dropout rate was
the same, with nine participants not responding to the
two communication attempts to complete assessments
after the post-intervention period or follow-up. In this
arm, it is possible that the participants lacked the motiv-
ation to stay in the trial and perhaps declined participa-
tion outside of the trial setting, which could also be due
to the long wait between baseline assessment and post-
intervention and follow-up assessment. The other possi-
bility is that perhaps the participants in the control were
disappointed that they were not selected to be in the
intervention arm, although they were offered the inter-
vention after all data were collected. This was at least
the case with the one participant that was excluded from
the trial after they breached the protocol and did the
intervention while in the control group. In addition, a
log was kept for the wait-list arm attending the inter-
vention after the completed assessments, and their
attendance was close to 100 %, with no drop-outs. Par-
ticipants in the wait-list arm remained motivated to
complete all the follow-up assessments because they
Schoultz et al. Trials  (2015) 16:379 Page 10 of 13knew they would be eligible for the intervention after all
data had been collected. In summary, while high drop-
out rates are a recognised occurrence in psychological
intervention trials [69–71], the demand for psychological
interventions in IBD is pertinent, and judging from
those that attended the intervention, it appears that
careful patient selection remains essential [72, 73].
Protocol adherence and success of data collection strategy
Complex psychological interventions are by definition
difficult to standardise and measure, and this always
should be considered [74]. Whereas a log of attendance
was kept for the intervention arm in this study, it was
very difficult to assess how much home practice the par-
ticipants did, and home practice was a particularly vital
component of the intervention. To be able to assess the
time spent on home practice and truly assess the effect-
iveness of the intervention in the future, a measurable
log of home practice might be introduced.
All data collected in the trial, including the consent
form, were collected by the lead researcher. This is par-
ticularly important to support a robust methodology, es-
pecially when front line clinicians’ priorities and time is
constrained. However, there is a debate that involving
clinicians in data collection is important, particularly in
context of culture and demonstrating the concept of
working together [75], and perhaps this should be con-
sidered in a future trial.
Data were collected at three time points, with the last
one at 6 months. The six-month follow-up was to assess
the mechanism of how feasible it is to collect follow-up
data for a full RCT, thereby assessing the sustainability
of any effectiveness of the intervention. Ideally, a longer
follow-up, such as 12 months, would give us better in-
formation about any sustainable changes in a full RCT.
Initially, the pilot considered testing the feasibility of
data collection at 12 months; however, there were few
points taken into consideration. The recruitment process
was stretched over a few months, and judging by the
dropout rate in both arms and literature [76], it could
have contributed towards further drop-outs in both
arms, predominantly in the wait-list arm if patients had
to wait even longer to be eligible to attend MBCT after
all follow-up assessments. In a future trial, this could be
overcome by having a designated research person work-
ing fulltime on recruitment, which could reduce the
recruitment time, thereby enable a shorter lag time be-
tween recruitment and the start of intervention.
Objective two: initial estimate on parameters of the proposed
outcome measures (depression, anxiety, dispositional
mindfulness, disease activity and quality of life)
With respect to the initial calculations on parameters for
the proposed outcome measures for a full RCT, alloutcome measures in the present study were validated
and found to be reliable measures. Although this ana-
lysis has its limitations due to the small sample size and
should not be generalised, it provides encouragement
that MBCT has the potential to help with management
of overall symptoms for IBD patients.
We measured the dependent variables (proposed out-
come measures) over time in the two different groups
and wanted to assess whether the dependent variables
responded differently over time in the groups. Thus, a
mixed ANOVA (with both between-subjects and within-
subject factors) analysis was conducted. For this analysis,
we looked at the group*time interaction where the group
(MBCT or wait-list) was the between factor, and time
(baseline, post-intervention and follow-up) was the
within factor [65]. We did the analysis for each of the
dependent variables: depression, anxiety, dispositional
mindfulness, disease activity and quality of life. This also
gave the initial estimates of the parameters to the pro-
posed outcome measures (mean and standard deviation)
required for a sample-size calculation for a future large
RCT [64].
The mixed ANOVA per protocol analysis showed a sta-
tistically significant interaction between the group (MBCT
and wait-list) and time (baseline, post-intervention and
follow-up) on depression (BDI-II), trait anxiety (STAI-Y2)
and dispositional mindfulness (MAAS) scores. This is par-
ticularly interesting as the literature suggests that high de-
pression and anxiety are closely linked with neuroticism.
In addition, the most common personality trait in IBD pa-
tients is reported to be neuroticism [77–80]. High neuroti-
cism scores are related to reduced psychosocial wellbeing,
psychological adjustment and quality of life in patients
with IBD [81] or higher depression and anxiety vulnera-
bility. Although we did not directly measure neuroticism
scores, their relation to depression, state anxiety and dis-
positional mindfulness has been well reported.
Considering that more than 30 % of IBD patients re-
port suffering from depression and that the preliminary
analysis showed that depression scores in the MBCT
group improved over time when compared to the con-
trol, these results are very promising. Further to this,
MBCT had significant effect on trait anxiety, whereas
the effect on state anxiety was not significant. This is
particularly interesting because changes in the trait anx-
iety scores suggest that they are not temporary changes
but they are more sustainable comparing to the state
anxiety. For example, a person who has a high trait
anxiety, views typical daily situation as more threatening
than those with lower trait anxiety and so responds with
a higher state anxiety. High trait anxiety is often linked
with neuroticism and higher vulnerability to depression
[82]. Reducing the trait anxiety could in return lower the
vulnerability for depression. In the long run, and taking
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tressing symptoms, the potential of MBCT to help IBD
patients to respond to daily situations, as well as the dis-
ease symptoms in a less stressful way, is certainly prom-
ising. Of course, to get a better idea of how sustainable
this is, a full RCT has to be conducted.
The other interesting finding was the improvement in
dispositional mindfulness scores. Dispositional mind-
fulness has been shown to moderate the relationship
between neuroticism and depressive symptoms [83]. A
study suggests that neuroticism is significantly related to
depression in those with low to medium levels of dispo-
sitional mindfulness but not in those with relatively high
levels of mindfulness. It also suggests that increased dis-
positional mindfulness may act as a protective factor
against the effects of negative emotional reactivity by
neuroticism. This could be very important for the future
tailoring of treatment based on patient characteristics
which is a well-accepted approach in IBD management
(for example, pharmacotherapy).
Disease activity, state anxiety and quality of life,
showed improvement over a period of time, but statis-
tical significance was not detected. This could be due to
the small numbers, particularly with the disease activity,
where the subgroup of CD and UC were very small to
compare between the two arms. The biggest surprise is
that quality of life change was very small and, in fact,
did not mimic the change in depression scores or trait
anxiety, as had been expected. One of the possible expla-
nations is that the sample was too small to detect any
significance. The second reason could be that the ques-
tionnaire used was an adapted version of the validated
IBDQ questionnaire and was not sensitive enough to de-
tect any real changes. What is also very interesting is that
in both arms, MBCT and the wait-list, there was a reduc-
tion in the quality of life scores at post-intervention, and
then increase of scores at the 6-month follow-up. It is
unclear whether any external factors contributed to this
or to the coincidental worsening in the quality of life for
both arms at post-intervention, with improvement at the
6-month follow-up.
Objective three: sample-size calculation
We estimated a sample-size calculation for a future trial
based on the dropout rate of this trial. However, we
should consider that the estimate from this study is only
an indication to what the ‘true’ dropout rate is, and per-
haps, the consideration of estimates from other trials
with similar type of intervention for this patient group
should be not dismissed.
Conclusions
We completed an exploratory pilot RCT despite chal-
lenges in recruitment. Based on the study findings andthe experience of conducting the pilot trial, we would
recommend a definitive multicentre trial with 129 par-
ticipants in each arm. Whereas the recommendations
for consent, randomisation and data collection are to be
conducted by a dedicated research team, recruitment
should be in collaboration with clinical staff, particularly
IBD specialist nurses, to maximise recruitment. Al-
though dropout rates were higher than expected, a future
trial could minimise this by decreasing the time lag be-
tween recruitment and start of intervention. Short tester
sessions could be offered to all potential participants to
help with appropriate patient selection and improving re-
tention. Retention rates were the same in both arms,
which suggests that randomisation was successful. A
measurable log of home practice should be introduced to
better assess protocol adherence and intervention com-
pliance and therefore determine the ‘true’ effectiveness of
the intervention. Information on medication or dosage
changes during the study period should be collected to
assess if it affects outcomes. The improvement in de-
pression, trait anxiety and dispositional mindfulness
scores in the intervention arm at post-intervention and
follow-up suggest that MBCT holds a potential to im-
prove overall symptom management and quality of life
for IBD patients.
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